Results 11 to 20 of about 39,213 (240)
Osteoprotegerin in Cardiometabolic Disorders [PDF]
International Journal of Endocrinology, 2015 Osteoprotegerin (OPG), a glycoprotein traditionally implicated in bone remodelling, has been recently related to cardiovascular disease (CVD). Human studies show a positive relationship between circulating OPG, vascular damage, and CVD, and as such OPG has emerged as a potential biomarker for CVD.
Pérez de Ciriza, C. +2 more
openaire +6 more sources
OSTEOPROTEGERIN, RANK, RANKL [PDF]
Biomedical Papers, 2001 Osteoprotegerin, RANK (Receptor Activator of Nuclear factor kappa B) and RANKL (Receptor Activator of Nuclear faktor kappa B ligand) became the aim of intensive research. RANK is considered as a hematopoietic surface receptor controlling osteoclastogenesis and calcium metabolism.
D, Stejskal +5 more
openaire +2 more sources
Effects of RANKL-Targeted Therapy in Immunity and Cancer. [PDF]
, 2014 The role of the receptor activator of nuclear factor-κB ligand (RANKL)/RANK system is well characterized within bone, where RANKL/RANK signaling mediates osteoclastogenesis and bone resorption.
Cheng, Michael L, Fong, Lawrence
core +2 more sources
Mechanisms by which sialylated milk oligosaccharides impact bone biology in a gnotobiotic mouse model of infant undernutrition [PDF]
, 2019 Undernutrition in children is a pressing global health problem, manifested in part by impaired linear growth (stunting). Current nutritional interventions have been largely ineffective in overcoming stunting, emphasizing the need to obtain better ...
Ahern, Philip P. +13 more
core +2 more sources
PLoS ONE, 2016 Osteoprotegerin, a potent osteoclast activation inhibitor, decreases bone resorption and positively affects bone mineral density. This study examined the association between serum osteoprotegerin levels and bone loss in patients with chronic kidney ...
Chang Seong Kim +10 more
doaj +1 more source
OSTEOPROTEGERIN AND BONE DENSITY [PDF]
Biomedical Papers, 2001 Aim of study was determine if a correlation exists between bone mass density and concentration of osteoprotegerin. We examined the group of 199 patients of mean age of 63 years. Of the group under study, 31 patients had normal bone density (T score > -1 and < 1) and 168 probands had osteopenia or osteoporosis (T < -1).
D, Stejskal +4 more
openaire +2 more sources
Medicina, 2022 Background and objective: There is limited information as to the association of several key bone markers with bone mineral density (BMD) in understudied ethnic groups. This study investigated the relationship between circulating levels of osteoprotegerin
Osama E. Amer +8 more
doaj +1 more source
Mathematical modelling of the pathogenesis of multiple myeloma-induced bone disease [PDF]
, 2014 Multiple myeloma (MM) is the second most common haematological malignancy and results in destructive bone lesions. The interaction between MM cells and the bone microenvironment plays an important role in the development of the tumour cells and MM ...
Blum B +6 more
core +1 more source
Diagnostics, 2021 Arterial stiffness (AS) is a complex vascular phenomenon with consequences for central hemodynamics and left-ventricular performance. Circulating biomarkers have been associated with AS; however, their value in heart failure is poorly characterized.
Lajos Fehérvári +7 more
doaj +1 more source
Rising plasma nociceptin level during development of HCC: A case report [PDF]
, 2004 AIM: Although liver cirrhosis is a predisposing factor for hepatocellular carcinoma (HCC), relatively few reports are available on HCC in primary biliary cirrhosis.
Folhoffer, Anikó +8 more
core +1 more source